Clinical Trials

Clinical Trials


Learn More About Our Clinical Trial

Merkel cell carcinoma is a rare and deadly disease. Despite a mortality rate of 40%, treatment options for these patients are scarce. Because 80% of Merkel cell carcinomas are caused by an associated viral infection (Merkel cell polyomavirus), it is believed that an efficient and targeted immunotherapy may be a potential therapeutic approach for this disease.

A Phase II safety and efficacy trial using OMS ElectroImmunotherapy to deliver DNA IL-12 in patients with local and metastatic Merkel cell carcinoma (OMS-I110) is being conducted in collaboration with the University of Washington. This open-label, multi-center Phase II trial will enroll approximately 15 patients with Merkel cell carcinoma. Trials are currently being conducted at two centers in the United States.

Enrollment for this clinical trial is currently underway. For further information about this trial,  Learn More

OMS-I100 – Phase II Metastatic Melanoma Clinical Trial

Approximately 70,000 new cases of melanoma will be diagnosed every year, and this number is increasing. Despite this cancer being the deadliest form of all skin cancers, there still remain few treatment options for patients with advanced-stage disease.

Previous data from a Phase I study demonstrated that using ImmunoPulse in melanoma patients is potentially safe and well tolerated. In addition, objective responses were observed in 53% (as defined by RECIST) of patients with metastatic disease, demonstrating promising anti-tumor activity.

A Phase II safety and efficacy trial using OMS electroporation to deliver DNA IL-12 in patients with late-stage metastatic melanoma (OMS-I100) is being conducted in collaboration with the University of California San Francisco. This open-label, multi-center Phase II trial will enroll approximately 25 patients with advanced-stage, cutaneous, in-transit malignant melanoma. Trials are currently being conducted at three centers across the United States.

Enrollment for this clinical trial is currently underway. For further information about this trial, Learn More

OMS-I120 – Phase II Cutaneous T-Cell Lymphoma Clinical Trial

Cutaneous t-cell lymphoma is a rare form of non-Hodgkin’s lymphoma that affects T-cells of the immune system, resulting in immune dysfunction. Though not life-threatening, this disease has proven difficult to treat, with current therapies unable to demonstrate long-term benefits.

As a disease of the immune system, cutaneous T-cell lymphoma may be responsive to immunotherapy, a treatment in which the immune system is stimulated to fight cancer and destroy infected cells. Immunotherapy has the potential to provide safe and long-lasting treatment.

A Phase II safety and efficacy trial using ImmunoPulse to deliver DNA IL-12 (a gene that triggers cells to attack and eliminate cancerous cells) in patients with early and late stage cutaneous T-cell lymphoma (OMS-I120) is being conducted in collaboration with the University of California San Francisco. This open-label, multi-center Phase II trial will enroll approximately 27 patients with cutaneous T-cell lymphoma. Trials are currently being conducted at one center in the United States.

Enrollment for this clinical trial is currently underway. For further information about this trial,  Learn More

Currently, the OMS has been tested for use with two anti-cancer therapies:

IMMUNOPULSE

ImunoPulse delivers a protein (DNA IL-12), which appears to stimulate the immune system toward targeting and killing cancer cells.

Learn More

Top

Download our Investor Overview:

Subscribe to Our Newsletter.

Subscribe to Our Newsletter:


Be the first to hear about new progress and breakthroughs at OncoSec.